About Adhera Therapeutics
Adhera Therapeutics was a publicly listed company based in Durham (United States) founded in 1983. It develops innovative small molecule therapeutics for hypertension. It operates on a B2B model. Adhera Therapeutics has completed 1 acquisition, including Cequent Pharmaceuticals. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Therapeutics and Hypertension Treatment. Its legal entity is MARINA BIOTECH, INC. Similar companies include Tenaya Therapeutics, Cellino and Arrakis Therapeutics; 3 of its 3 listed similar companies have raised funding.
Company details
Adhera Therapeutics, established in 1983 and currently in Dissolved stage, focuses on providing healthcare solutions, producing pharmaceutical products, therapeutics, and hypertension treatment. Develops innovative small molecule therapeutics for hypertension. Adapting to market demands with innovation and client-focused strategies. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Durham, United States
- Stage Public
- SectorsHealthcare
- Website adherathera.com
- Legal Name Adhera Therapeutics Inc.
- Net Profit-$2.11 M (USD)66.71as on Dec 31, 2022
- EBITDA-$1.62 M (USD)-140.06as on Dec 31, 2022
- Latest Funding Round$499.95K (USD), Post-IPO
Feb 2020
- Investments & Acquisitions
Funding Insights of Adhera Therapeutics
- Total Rounds 14
- Last Round Post-IPO — $499,950
- First Round $4.2M
(Mar 2001)
Latest 10 of 14 funding rounds of Adhera Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $499,950 | Post-IPO | – | – | – |
| Jul 2019 | $3.24M | Debt – Conventional | – | – | – |
| Jul 2018 | $1.5M | Post-IPO | – | – | – |
| Apr 2018 | $11.67M | Post-IPO | – | – | – |
| Nov 2017 | $500,000 | Post-IPO | – | – | – |
| Jun 2017 | $224,366 | Post-IPO | – | – | – |
| Jun 2016 | $300,000 | Post-IPO | – | – | – |
| Aug 2015 | $1.1M | Post-IPO | – | – | – |
| Mar 2014 | $6M | Post-IPO | – | – | – |
| Feb 2012 | $1.5M | Debt – Conventional | – | – | – |
IPO & Listings of Adhera Therapeutics
Adhera Therapeutics is a publicly listed company on the OTC with ticker symbol ATRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Dec 1993
- Listed onOTCMKTS: ATRX
- Listed entityAdhera Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS00687E4061
- Share price$0.00 · 2026-10-07
- Market capitalisation$722.09
- Volume (last session)20,000
Financials of Adhera Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2022 | -$2.1M | -$1.6M | |
| 2021 | -$6.3M | -$674,000 | |
| 2020 | -$3.8M | -$2.0M |
Detailed financial statements for Adhera Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adhera Therapeutics
Adhera Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cequent Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Novel therapeutics for diseases are developed using proprietary tkRNAi technology. | cequentpharma.com | Cambridge, United States | 2006 | Apr 2010 | $46M |
Complete acquisition details for Adhera Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Adhera Therapeutics
5 dated milestones of Adhera Therapeutics across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Adhera Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $4.2M.
- Acquisition Acquires Cequent Pharmaceuticals.
- Funding Latest funding round, Post-IPO, of $500K.
Similar companies to Adhera Therapeutics
Adhera Therapeutics has 3 listed similar companies in our database, 3 of them funded. They include Tenaya Therapeutics, Cellino and Arrakis Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures |
Detailed similar companies of Adhera Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Adhera Therapeutics (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adhera Therapeutics
Complete news archive for Adhera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adhera Therapeutics
Adhera Therapeutics was founded in 1983 and raised its 1st funding round 18 years after it was founded.
Adhera Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Adhera Therapeutics, established in 1983 and currently in Dissolved stage, focuses on providing healthcare solutions, producing pharmaceutical products, therapeutics, and hypertension treatment. Develops innovative small molecule therapeutics for hypertension. Adapting to market demands with innovation and client-focused strategies. It continues to evolve, meeting industry challenges with strategic approaches.
Adhera Therapeutics's top competitors include Tenaya Therapeutics, Cellino and Arrakis Therapeutics.
Yes, Adhera Therapeutics is publicly traded on OTC under the ticker symbol ATRX.
Adhera Therapeutics has made 1 acquisition, including Cequent Pharmaceuticals.
Adhera Therapeutics operates through Marina Biotech, Inc..